v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2018
Jun. 30, 2018
Current assets:    
Cash $ 13,361 $ 15,934
Accounts receivable - trade 155 75
Contract assets 57 0
Prepaid expenses and other current assets 396 276
Total Current Assets 13,969 16,285
Fixed assets, net of accumulated depreciation 24,812 25,152
Intangible assets, net of accumulated amortization 1,498 1,620
Security deposits 24 26
Total Assets 40,303 43,083
Current liabilities:    
Accounts payable (related party of $79 and $189 as of December 31, 2018 and June 30, 2018, respectively) 662 790
Accrued expenses (related party of $651 and $789 as of December 31, 2018 and June 30, 2018, respectively) 1,052 1,048
Capital lease obligation – current portion 205 197
Contract liabilities 2,526 0
Total Current Liabilities 4,445 2,035
Capital lease obligation - net of current portion 24,780 24,884
Total Liabilities 29,225 26,919
Commitments and Contingencies
iBio, Inc. Stockholders' Equity:    
Common stock - $0.001 par value; 275,000,000 shares authorized; 18,836,792 and 16,040,126 shares issued and outstanding as of December 31, 2018 and June 30, 2018, respectively 19 16
Additional paid-in capital 108,188 104,408
Accumulated other comprehensive loss (30) (30)
Accumulated deficit (97,095) (88,228)
Total iBio, Inc. Stockholders' Equity 11,082 16,166
Noncontrolling interest (4) (2)
Total Equity 11,078 16,164
Total Liabilities and Equity 40,303 43,083
iBio CMO [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series A Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series B Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued $ 0 $ 0

Source

v3.10.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Revenues $ 651 $ 153 $ 696 $ 275
Operating expenses:        
Research and development (related party of $285, $197, $544 and $373), net of grant income of $37, $0, $37 and $44 1,273 993 2,397 1,978
General and administrative (related party of $311, $181, $572 and $387) 3,393 2,587 6,264 5,085
Total operating expenses 4,666 3,580 8,661 7,063
Operating loss (4,015) (3,427) (7,965) (6,788)
Other income (expense):        
Interest expense (related party of $476, $479, $952 and $959) (476) (479) (952) (959)
Interest income 23 4 44 9
Royalty income (expense) (2) 2 4 11
Total other income (expense) (455) (473) (904) (939)
Consolidated net loss (4,470) (3,900) (8,869) (7,727)
Net loss attributable to noncontrolling interest 1 1 2 2
Net loss attributable to iBio, Inc. (4,469) (3,899) (8,867) (7,725)
Preferred stock dividends (65) (65) (131) (131)
Net loss available to iBio, Inc. (4,534) (3,964) (8,998) (7,856)
Comprehensive loss:        
Consolidated net loss (4,470) (3,900) (8,869) (7,727)
Other comprehensive income (loss) - foreign currency translation adjustments 1 0 0 0
Comprehensive loss $ (4,469) $ (3,900) $ (8,869) $ (7,727)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.24) $ (0.41) $ (0.49) $ (0.82)
Weighted-average common shares outstanding - basic and diluted 18,688 9,661 18,291 9,613

Source

v3.10.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Cash flows from operating activities:    
Consolidated net loss $ (8,869) $ (7,727)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:    
Share-based compensation 133 394
Amortization of intangible assets 151 169
Depreciation 724 679
Write-off of fixed assets 179 0
Changes in operating assets and liabilities:    
Accounts receivable – trade (79) 39
Contract assets (57) 0
Work in process 0 26
Prepaid expenses and other current assets (121) (94)
Security deposits 1 0
Accounts payable (40) (163)
Accrued expenses 4 206
Contract liabilities 2,526 (134)
Net cash used in operating activities (5,448) (6,605)
Cash flows from investing activities:    
Additions to intangible assets (30) (35)
Purchases of fixed assets (648) (277)
Net cash used in investing activities (678) (312)
Cash flows from financing activities:    
Proceeds from sale of common stock 1,350 5,500
Costs to raise capital (159) (321)
Proceeds from capital contribution 2,459 0
Proceeds from additional paid-in capital – preferred stock 0 1,050
Payment of capital lease obligation (97) (90)
Net cash provided by financing activities 3,553 6,139
Net decrease in cash (2,573) (778)
Cash - beginning of period 15,934 8,088
Cash - end of period 13,361 7,310
Schedule of non-cash activities:    
Unpaid intangible assets included in accounts payable 1 22
Intangible assets included in accounts payable in prior period, paid in current period 3 11
Fixed assets included in accounts payable in prior period, paid in current period 85 87
Unpaid fixed assets included in accounts payable 0 188
Supplemental cash flow information:    
Cash paid during the period for interest $ 953 $ 960

Source